Privia Health Group, Inc. (NASDAQ:PRVA) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. lifted its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 62.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 290,009 shares of the company’s stock after acquiring an additional 110,960 shares during the quarter. Victory Capital Management Inc. owned 0.24% of Privia Health Group worth $5,670,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Riverbridge Partners LLC increased its stake in Privia Health Group by 19.7% in the fourth quarter. Riverbridge Partners LLC now owns 5,824,458 shares of the company’s stock valued at $113,868,000 after purchasing an additional 958,418 shares during the last quarter. Eventide Asset Management LLC boosted its holdings in shares of Privia Health Group by 979.2% in the third quarter. Eventide Asset Management LLC now owns 822,438 shares of the company’s stock valued at $14,977,000 after acquiring an additional 746,231 shares in the last quarter. Icon Wealth Advisors LLC raised its stake in shares of Privia Health Group by 1,910.1% during the 3rd quarter. Icon Wealth Advisors LLC now owns 300,889 shares of the company’s stock worth $5,479,000 after buying an additional 285,920 shares in the last quarter. FMR LLC lifted its holdings in Privia Health Group by 1.5% in the third quarter. FMR LLC now owns 18,169,043 shares of the company’s stock valued at $330,858,000 after acquiring an additional 271,645 shares during the period. Finally, Barclays PLC boosted its holdings in Privia Health Group by 240.3% during the third quarter. Barclays PLC now owns 224,018 shares of the company’s stock worth $4,079,000 after buying an additional 158,188 shares in the last quarter. 94.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on PRVA. JPMorgan Chase & Co. increased their price target on shares of Privia Health Group from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, November 29th. Macquarie began coverage on shares of Privia Health Group in a research report on Monday, December 16th. They set an “outperform” rating and a $25.00 price target for the company. Stephens reiterated an “overweight” rating and set a $26.00 target price on shares of Privia Health Group in a report on Thursday, January 2nd. Piper Sandler upped their target price on Privia Health Group from $25.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Finally, Canaccord Genuity Group upped their price objective on shares of Privia Health Group from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $26.67.

Privia Health Group Trading Up 1.6 %

NASDAQ:PRVA opened at $23.75 on Friday. The firm has a market capitalization of $2.86 billion, a PE ratio of 237.52, a price-to-earnings-growth ratio of 3.47 and a beta of 0.85. The stock has a 50 day moving average of $23.36 and a 200-day moving average of $20.91. Privia Health Group, Inc. has a 52 week low of $15.92 and a 52 week high of $26.04.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.